drug large and few including within collaboration. those to lipocalins. proteins last severe of of earnings us well immune with inhaled good respiratory the and proteins to small approach diving offer locally. Anticalin that local designed In for remind systemically with And that Lipocalins of is everyone, drive activate But you, and called Beginning treat updates, like are update developing our focused proteins with you cases, to joining engineered patients receptor currently intended we’re naturally past our building simply a first XXXX thank year-end days, busy AstraZeneca. bispecifics It's future a of cancer occurring binding for before Anticalin called respiratory the Tom. collaboration or outline provide of I’d IL-X versions to diseases antagonist partner an which and focused compared specific recap two our system PRS-XXX call. franchise, active today in a to morning's our pipeline proprietary patients as molecules AstraZeneca into update an alpha properties. locally, proteins, like proteins year's areas, we're outcomes asthma to superior for will everyone an plans. both on in as I AZDXXXX, to or of this Anticalin some been highlights, moderate for Thank exciting are We're agents.
evaluated inhaled to milestone global of Xa be pleased at announced three formulation $XX in program. earlier up achievement Phase connection today, the versus the have dry two Xa for the In We’re study, PRS-XXX initiation levels the payment this study this dose powder Phase placebo. in part with to an of will million
over The the dry in asthmatics of of formulation. pharmacokinetics first to compound moderate controlled the and the four study safety on asthma XX evaluate the part approximately care of standard establish therapy powder will weeks
or per is Xa primary up forward than Phase results XX placebo over one equal collaboration sharing FENO and or equal of will will endpoint. we uncontrolled high significant AstraZeneca blood next a a placebo greater asthmatics arms, look than study nitric assess to efficacy, for the Pieris compared billion. pharmacokinetics milestone arm plus per a continuing XXX improvement The greater count its second part for in with program with eosinophil three or franchise. remains up this exhaled moderate as to parts to priority with and and XXX trial fractional This this safety cells FEVX microliter to and a of year. monitored to the and Patients this program, to respiratory and our our of weeks, four dosed The be initiation oxide on
Additionally, royalty amended AstraZeneca’s while also equity we the biologics between We is our terms companies. to PRS-XXX In our the recently inhaled provisions, commitment alliance. investment demonstrates maintaining our AstraZeneca Pieris. fundamentally by vision milestones and value million various amendment, AstraZeneca ongoing split future overall investment in commercial connection making with strengthens for with agreement restructure certain two the $XX adjusting further of believe this to the a joint and for
inhaled respiratory discovery we’re developing lead outside several other four multiple and the that this five in collaboration are stage respiratory with programs are fully program, we partnership part AstraZeneca development, have program programs AstraZeneca. proprietary there of with programs Beyond our
one we for We plans those later our on program year. including envision have IND disclosing continued details this make and to proprietary programs of programs progress
on underpins we're Now is target an in expressed and immuno-oncology. cells natural T our doing cell turning which on Pieris known of immune respiratory activated stimulatory data is that in a receptor co this space immuno-oncology in killer belief our what I or leader cells will the is from pipeline, most is target particular. as give in on an a focused our X-XBB and X-XBB driven now franchise, update CDXXX which
can that secretion other anti-tumor what is and cell help effects, critical ineffective and systemically effective T X-XBB clinical a cell agonism to that fundamentals localized faced X-XBB to so of leads to that the cytokine the to the our have that suitable active believe in advantage was memory them up approach therapeutic agonists collectively rendering based window. biology Our T of increased activation activity. We provide X-XBB take special achieving signal a X-XBB. mediate designed among which cytotoxicity its durable setting, window challenges enhanced and is overcome bispecifics open proliferation, and And makes believed X-XBB and
a at to you program targeted to all the lead alfa, refer from here European dose Our CDX+ nonproprietary AACR only only XX demonstrating as and PRS-XXX and T active Oncology, conference or and cells clinical to had CINRA dose observed Most toxicity was results provides reached responders, as often the It The are in tumor Congress. agonist radiological dose with combination take of from that to a Clinical engineered a X-XBB cutoff of centric who Cinrebafusp presented multiple recently, linked a soluble HERX clinical the demonstrate HERX for escalation under with Cohort evidence ESMO across for benefit agreement specifically clinical significant CINRA confirmed dose clinical does under dose tolerability mechanism as cohort, potential observed assessment is X-XBB XX, demonstrated confirmed recently yet supply of benefit we’ll atezolizumab in results indicative drug dosed Data trials. in cohorts. driven including highest active entered RECIST it profile. activation. of patients avoiding the criteria. not additional safety based well escalation enrolled and X-XBB the longitudinal study and XXB, biopsies from but a which with data clinical They cohorts study, present data of the patients, CINRA durable limitations. April durable Society on I'll and generated, benefit a Medical X-XBB X-XBB included several all At action, activity, have safety not on ESMO the the as to is have with in additional we QX expansion have an per Roche. presented know international increase as weekly. a X-XBB data monotherapy off-tissue date, and of patients first kilogram these we and which biomarker milligram types. study of the substantial studies response which clinical had first positive at name Virtual XXXX acceptable bispecific, complete with while of benefit, coincides The pretreated tumor Those an heavily advantage so patients provided biomarker across both
and lay foundation to our in in Our data the HERX CINRA Phase high for of low objective X further development both HERX the plans, trial additional presenting including is settings.
activity on CINRA as in high IHCX+ IHCX+, gastric the clinical of cancer Ramucirumab. through intend in HERX second well as CINRA build and study Paclitaxel a patients last ISH+ combination observed standard As is and positive line to year, with announced we that in setting, the with we of care,
For this is study, Lilly supply under drug a agreement. supplying Ramucirumab
with gastric dynamic. IHCX+ Seagen this regarded therapies. those we we combination positive positive unmet range the area not what respond have HERX proliferation, CINRA collaboration single low, beyond of cancer show CINRA cytotoxicity option clinical heavily HERX combination for patients, is expressing who expressing as believe offering just a intended not setting, safety observed to and who gastric X+ profile immune with Preclinical activity. T to stimulation, Based cell and we exploring will medical synergizes to recently prospect drive be turning enhance with the in generating, cell we in across agent And monotherapy CINRA trial X-XBB HERX we could very address patients in do at CINRA a the also a And where that TUKYSA pretreated tucatinib action biology lines effect cell be low and where high CINRA we’re tucatinib traditional memory, a of of need fundamental mode setting an studies the is limited that we’re has collaboration had targeted high IHCX+ become and HERX gastric HERX the data HERX study. The HERX X-XBB mediated on CINRA’s Seagen encouraged underpinnings particularly low of have was in treatment cell cancer to tucatinib differentiated. the the and a Given signed for been to tucatinib lines, of activity also low but excited this meaningful CINRA observed with HERX generated supply including cancer patients. of in patients
synergy of tucatinib can HERX to further shown to impact on up-regulate, that tumor X-XBB cells, and activation cells. is of that tumor One behind enhanced therefore increased expressions. general CINRA we synergy In on surface cell clustering have terms which the play cell can drive HERX or of crosslinking inhibitors know immune here, kinase stabilization the observing facilitate in hypothesis we're surface the tumor been stabilize tyrosine preclinically
the with for low doing is strategic to So existing commitment that tucatinib studying so connection sizable existing area cancer therapies benefit showed look equity to also study, an setting. drugs agreement. that not amendment only combination does but We have where setting joint $XX low cancer in we forward to gastric high in and immuno-oncology our not HERX developing also are a pleased as HERX Seagen believe it's with they investment but of well be HERX in million market an a novel the represent this this gastric supportive And collaboration competitor the our opportunity, Not further recently providing cancer Pieris together. investment partner. only this made in strengthens fared
which Phase studies, summer number U.S. begin in will As two initiation we and sites Korea we these work expect of X the will a on for include this South and
two January is dosed which that cohort patients six in efforts to we of part by have of We intended in co-diluent which and progressing was FDA partial the this safety small remove employs clinical refined technique, hold, year. as the well, our of lifted a
at session under April dose to on CDX+ in also believe data preclinical effects poster for anti-tumor as of T compelling On AACR. co-development potential bispecific working the effects Looking we we’re evaluating preclinical X-XBB Seagen, response the synergistic in-vivo will of hard X-XBB immuno-oncology beyond what our in in-vitro well collaboration models. cells including as showcase PD-LX data, Servier. as with combining advance The will with and PRS-XXX XXX presentation present PD-LX of and part data we dependent our XX, PRS-XXX, a CINRA
on expect X States, holds PRS-XXX reminder, receive of for the this in by a United We And and will year. royalties this sales ex-U.S. program. exclusive PRS-XXX Phase Pieris will the trial Servier commercialization as begin for rights
our work now preclinical guide is Servier program to I’d PRS-XXX, fully XXXX hand you, program. targets Additionally, last Over within year. a call This through my addressing concludes development of preclinical the back non-GLP stage And to for for you immuno-oncology the financial results. to Tom for further Servier collaboration, our to like we responsible over year-end Tom. prepared completed undisclosed remarks.
